Patient characteristics
| Characteristic . | Duration of CSP prophylaxis . | |
|---|---|---|
| 6 months (n = 73) . | 24 months (n = 89) . | |
| Patient age | ||
| Less than 20 years | 15 (21) | 12 (13) |
| 20 years or older | 58 (79) | 77 (87) |
| Donor/recipient sex | ||
| Female/female | 14 (19) | 18 (20) |
| Female/male | 14 (19) | 19 (21) |
| Male/female | 22 (30) | 19 (21) |
| Male/male | 23 (32) | 33 (37) |
| Donor type | ||
| HLA-identical sibling | 29 (40) | 39 (44) |
| Other | 44 (60) | 50 (56) |
| History of grades II-III GVHD | ||
| No | 17 (23) | 22 (25) |
| Yes | 56 (77) | 67 (75) |
| Skin biopsy results* | ||
| Negative | 27 (37) | 34 (38) |
| Positive | 46 (63) | 55 (62) |
| Treatment with prednisone* | ||
| No | 8 (11) | 7 (8) |
| Yes | 65 (89) | 82 (92) |
| Characteristic . | Duration of CSP prophylaxis . | |
|---|---|---|
| 6 months (n = 73) . | 24 months (n = 89) . | |
| Patient age | ||
| Less than 20 years | 15 (21) | 12 (13) |
| 20 years or older | 58 (79) | 77 (87) |
| Donor/recipient sex | ||
| Female/female | 14 (19) | 18 (20) |
| Female/male | 14 (19) | 19 (21) |
| Male/female | 22 (30) | 19 (21) |
| Male/male | 23 (32) | 33 (37) |
| Donor type | ||
| HLA-identical sibling | 29 (40) | 39 (44) |
| Other | 44 (60) | 50 (56) |
| History of grades II-III GVHD | ||
| No | 17 (23) | 22 (25) |
| Yes | 56 (77) | 67 (75) |
| Skin biopsy results* | ||
| Negative | 27 (37) | 34 (38) |
| Positive | 46 (63) | 55 (62) |
| Treatment with prednisone* | ||
| No | 8 (11) | 7 (8) |
| Yes | 65 (89) | 82 (92) |
Values are numbers (percentages).
CSP indicates cyclosporine; GVHD, graft-versus-host disease.
At time of enrollment.